NCT01356940 is a Phase 4 clinical trial of dalfampridine ER in Multiple Sclerosis, sponsored by Brown, Theodore R., M.D., MPH.

Who is sponsoring NCT01356940?

NCT01356940 is sponsored by Brown, Theodore R., M.D., MPH.

What drugs are being tested in NCT01356940?

Interventions in NCT01356940: dalfampridine ER, placebo.

What condition does NCT01356940 study?

NCT01356940 studies Multiple Sclerosis.

Is NCT01356940 still recruiting?

NCT01356940 is currently completed. Last updated 3 October 2018.

Are results published for NCT01356940?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-10-03 · How we verify

NCT01356940

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple Sclerosis

Completed Phase 4 Results posted Last updated 3 October 2018

What this trial tests

Phase 4 trial testing dalfampridine ER in Multiple Sclerosis in 43 participants. Completed in 1 April 2013.

Timeline

1 November 2010

Primary endpoint
1 April 2013

1 April 2013

Quick facts

Lead sponsor	Brown, Theodore R., M.D., MPH
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	43
Start date	1 November 2010
Primary completion	1 April 2013
Estimated completion	1 April 2013
Sites	1 location across United States

Drugs / interventions tested

dalfampridine ER — full drug profile →
placebo

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Brown, Theodore R., M.D., MPH — full company profile →

Who can join

Adults 18 to 75, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Peak Activity Index
Time frame: 10 weeks
peak activity index is a measure of the 30 fastest minutes of walking over a 24 hour period, averaged over one week of accelerometer wear. Measurement is change from baseline to 4 weeks on intervention

Sponsor's own description

A randomized placebo controlled double-blind cross-over trial of Dalfampridine ER for effect on ambulatory activity in people with multiple sclerosis

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01356940 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brown, Theodore R., M.D., MPH
Last refreshed: 3 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01356940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing